What are eligibility criteria in clinical trials?

Eligibility criteria are the requirements that must be met to join a particular clinical trial. The National Cancer Institute says every trial has them, and they are set before the study opens rather than adjusted case by case.

NCI lists what they commonly cover: health, medical history, family medical history, risk factors, age, treatment history, and the genetic changes in the tumor.

What they look like in a real protocol

Criteria come in two halves. Inclusion criteria say who may join. Exclusion criteria say who may not. Both are usually written as precise thresholds with dates attached, which is why they can feel unforgiving.

Take a currently recruiting study registered as NCT06336928, which is testing whether a blood test agrees with a breast cancer diagnosis. Its inclusion criteria require women aged 18 or older, and then split into four groups by situation. One group is a new biopsy-proven breast cancer diagnosed within 60 days of the blood draw, with no cancer-directed treatment started yet.

The exclusion criteria rule out anyone unable to give informed consent. They also rule out a blood transfusion within 14 days of the study blood draw, a heart attack, stroke, or blood clot in the lung within 3 months of it, and a surgical breast biopsy in the prior 30 days. A needle biopsy of the breast is allowed.

Notice how specific those windows are. Fourteen days. Three months. Thirty days. Those numbers exist because a recent transfusion or a recent operation would change what the blood test measures.

Why the rules are drawn so tight

Three reasons, and NCI names all three. Criteria reduce the medical differences among people in the trial. They reduce the risk that people will be harmed. And they limit the trial to those most likely to benefit.

Underneath sits the whole point of a study. NCI puts it plainly: when people taking part are alike in specific ways, researchers can be more certain that the results are due to the treatment being tested and not to other factors.

The two stages that decide it

They are not the same, and the difference matters.

Pre-screening comes first. NCI describes it as a meeting where a study team member, such as a research nurse or study coordinator, explains the trial and asks questions to see whether the person might be able to join. That conversation may cover the goals of the trial, the drug being tested and what is known about its side effects, the number of visits required, the support the trial provides, and insurance coverage and alternatives.

Screening happens around the time the consent form is signed. NCI says the study team reviews the medical history and runs any necessary tests to confirm all requirements are met, and that it is more thorough than pre-screening.

That second stage can end things. NCI is explicit: someone may not be able to take part based on their medical history or test results, even after clearing pre-screening.

Being turned down says nothing about the next trial

Failing one study's criteria carries no verdict. Trials are built for different questions, and a study of one tumor mutation will have different requirements from a broad study open to everyone with that cancer type.

Two moves help. Ask which specific criterion excluded you, since several are time-limited and stop applying after a waiting period. And ask whether the site has other open studies, or whether the treating team can search elsewhere.

The protocol is the document behind all of it. NCI describes it as a detailed plan covering the goal, who is eligible, participant protections, testing and procedures, the length of the trial, and what information will be collected. Our guide to clinical trial eligibility criteria goes deeper into common exclusions, and finding a clinical trial covers where to search.

Sources

• https://www.cancer.gov/research/participate/clinical-trials/how-trials-work
• https://www.cancer.gov/research/participate/clinical-trials/what-to-expect
• https://clinicaltrials.gov/api/v2/studies/NCT06336928